On Monday, Tarsus Pharmaceuticals hit an important performance benchmark, seeing its Relative Strength (RS) Rating jump into the 90-plus percentile with an improvement to 93, up from 90 the day before.
This unique rating tracks technical performance by using a 1 (worst) to 99 (best) score that identifies how a stock's price action over the last 52 weeks matches up against other publicly traded companies.
Decades of market research shows that the top-performing stocks typically have an 80 or better RS Rating as they launch their biggest runs.
Looking For The Best Stocks To Buy And Watch? Start Here
Tarsus Pharmaceuticals is trying to complete a double bottom with a 52.63 entry. See if the stock can clear the breakout price in heavy trade.
The company posted 0% EPS growth last quarter, while sales growth came in at 408%. The next quarterly numbers are expected on or around May 13.
Tarsus Pharmaceuticals earns the No. 28 rank among its peers in the Medical-Biomed/Biotech industry group. ADMA Biologics, Catalyst Pharmaceuticals and GeneDx Holdings are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Rising Relative Strength?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
